DSP-2230 is a selective small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker which is under development by Dainippon Sumitomo Pharma for the treatment of neuropathic pain.[1][2] As of June 2014, it is in phase I/phase II clinical trials.[1][2]
Clinical data | |
---|---|
Routes of administration | By mouth |
Identifiers | |
| |
CAS Number |
|
UNII |
|
ChEMBL |
|
Chemical and physical data | |
Formula | C20H20F3N5O2 |
Molar mass | 419.408 g·mol−1 |
3D model (JSmol) |
|
| |
|